News » Visby Reaffirms Support for Women’s Access to Healthcare

06/27/2022Press Release

Visby Reaffirms Support for Women’s Access to Healthcare

Visby Medical’s CEO reaffirms support for women’s healthcare access, announcing travel expense reimbursement for employees for out-of-state pregnancy-related care.

Visby Reaffirms Support for Women’s Access to Healthcare

SAN JOSE, Calif., June 27, 2022Visby Medical™, a leading medical diagnostic company, announced in an internal communication to employees Friday that the company will provide travel benefits for any employee, or their dependents, to travel to another state to obtain safe and legal pregnancy-related care. The new policy, effective immediately, is a direct response to the recent decision by the U.S. Supreme Court to overturn Roe v. Wade. The new Visby policy ensures that its employees and their dependents will continue to have access to safe and legal reproductive health care.

The idea that patients deserve autonomy in their own health, including sexual and reproductive health, is at the heart of Visby’s mission. The company and its employees are working to expand access to infectious disease healthcare, especially in underserved and disadvantaged communities which are more likely to be negatively impacted by restrictions to reproductive healthcare.

“Visby Medical was founded on the notion that every person deserves equitable access to quality healthcare, and we started with sexually transmitted infections in women because we felt this is where the greatest inequities and lack of access are,” said Visby Medical Founder and CEO Adam de la Zerda. “The Supreme Court’s decision is certainly a step in the opposite direction for patient access. While we cannot fix all the world’s problems, we reaffirm our conviction that making the healthcare system more equitable and accessible to all patients is critically important. We are committed to supporting our employees and protecting their right to make immensely personal decisions about their own health, and we will not allow this court decision to endanger the health and well-being of our employees and their families, regardless of where they live.”

Visby’s revolutionary PCR technology was developed with the goal of broader and faster access to healthcare and increased individual autonomy and decision-making. The Sexual Health Click Test was designed to quickly inform diagnosis during the visit, so clinicians can discuss results with patients and make accurate, personalized treatment decisions. This same principle guides the company’s policy update in the wake of the recent Supreme Court decision.

About Visby Medical™
Visby Medical is transforming the order of diagnosis and treatment for infectious diseases so clinicians can test, talk with, and treat the patient in a single visit. The Company’s proprietary technology development program culminated in the world’s first instrument-free, single-use PCR platform that fits in the palm of your hand and rapidly tests for serious infections. Originally developed for sexually transmitted infections, the Company’s FDA-cleared, CLIA-waived Sexual Health Click Test for women returns accurate results within 28 minutes. The Visby Medical technology is also helping to fight the global pandemic via the Visby Medical COVID-19 Test, and its robust pipeline includes tests for other infectious diseases. Visby Medical is accelerating the delivery of fast and accurate, palm-sized PCR diagnostics to the point of care, and eventually for use at home.

For more information, visit www.visbymedical.com. Follow Visby Medical on LinkedInFacebook, and Twitter.

Media Contact
press@visby.com

Investor Contact
Mark Ibison
Chief Financial Officer, Visby Medical
mark.ibison@visby.com

Read more articles & insights

05/11/2023Viewpoint

Navigating the Post-Public Health Emergency Landscape: How the Visby Medical Respiratory Health Test EUA Remains Unaffected

As we move into the post-public health emergency landscape with the expiration of the national emergency concerning the coronavirus disease 2019 (COVID-19) pandemic on May 11, 2023, it is essential to understand how the healthcare industry has adapted and evolved to address the unique challenges posed by the COVID-19 pandemic.

Read More
Navigating the Post-Public Health Emergency Landscape: How the Visby Medical Respiratory Health Test EUA Remains Unaffected

03/14/2023Press Release

Visby Medical™ Receives FDA Clearance and CLIA Waiver for second Generation Sexual Health Test for Women

Visby Medical™ announced today that it has received 510(k) clearance and was granted a CLIA waiver from the FDA for its 2nd generation point of care (POC) test.

Read More
Visby Medical™ Receives FDA Clearance and CLIA Waiver for second Generation Sexual Health Test for Women

01/03/2023Press Release

Visby Medical Receives FDA Emergency Use Authorization for Respiratory Health Test for Use in CLIA Waived Settings

Visby Medical announced today that it has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration for its Respiratory Health point of care test.

Read More
Visby Medical Receives FDA Emergency Use Authorization for Respiratory Health Test for Use in CLIA Waived Settings

06/10/2023Viewpoint

Everything You Need to Know about Trichomonas Featuring Dr. Ina Park

CME on-demand webinar presented by ASHA | A comprehensive guide for the detection and management of the often neglected sexually transmitted infection, Trichomoniasis.

Read More
Everything You Need to Know about Trichomonas Featuring Dr. Ina Park